A Phase III trial of an inactivated COVID-19 vaccine developed through Chinese state pharmaceutical company Sinopham began in the United Arab Emirates in July and is not yet complete.
“The vaccine will be available to our first line of defense heroes who are at greatest threat to contract the virus,” the National Crisis and Disaster Management Authority said in a tweet.
The announcement comes amid an increase in the number of new instances of COVID-19 in the United Arab Emirates, which reported 1,007 instances on Saturday, since the start of the pandemic, there were 777 new instances on Monday.
Emergency use of the vaccine, which is still being tested, was granted after a number of criteria and after being tested on 31,000 volunteers, he said.
Mild and expected side effects occurred, however, there were no serious side effects, the signature said without giving further details. He added that a thousand other chronic people who participated saw no complications.
Sinopharm was approved for the trial at the end of June. The experimental vaccine passed Phases I and II of clinical trials with one hundred percent of volunteers generating antibodies after two doses in 28 days, according to a report from the Abu Dhabi government in July.
According to the Centers for Disease Control, inactivated vaccines, made with inactivated (dead) viruses or a virus protein, are known and have been used against diseases such as influenza and measles.
In August, Russia was the first country in the world to grant regulatory approval for a coronavirus vaccine after less than two months of human testing.
This story was published from a firm thread without converting the text. Only the name has been changed.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Login to our to save your favorites. It will only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.